Journal Article

Hodgkin's Disease in the Setting of Human Immunodeficiency Virus Infection

Alexandra M. Levine

in JNCI Monographs

Volume 1998, issue 23, pages 37-42
Published in print April 1998 | ISSN: 1052-6773
Published online April 1998 | e-ISSN: 1745-6614 | DOI: https://dx.doi.org/10.1093/oxfordjournals.jncimonographs.a024171
Hodgkin's Disease in the Setting of Human 
Immunodeficiency Virus Infection

Show Summary Details

Preview

Although Hodgkin's disease (HD) is not usually associated with congenital or acquired immunodeficiency disorders, recent evidence would suggest a statistically significant increase in HD among individuals infected with human immunodeficiency virus (HIV). In the setting of underlying HIV infection, clinical and pathologic characteristics of HD may differ from usual expectations. Thus, 70%-100% of HIV-infected patients with HD present with systemic “B” symptoms. Likewise, disseminated, stage III or IV disease is reported in approximately 75%-90%. Bone marrow is a common site of extranodal HD, occurring in 40%-50%. Complete response rates after multiagent chemotherapy range from approximately 45% to 70%, although median survival has been only in the range of approximately 18 months. Hematologic toxicity from multiagent chemotherapy may be substantial, even with the use of hematopoietic growth factor support. It is apparent that new strategies of therapeutic intervention must be explored.

Journal Article.  5738 words. 

Subjects: Medical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content. subscribe or login to access all content.